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Background: Tamoxifen is the most widely used anti-estrogen for the treatment of breast cancer. Studies show
that the combination therapy with other substances that helps the activity of tamoxifen. The objective of this study
was to evaluate the effect of tamoxifen when used in combination with tranilast on human breast cancer cells.
Results: Two MCF-7 and MDA-MB-231 human breast cancer cell lines were treated with tamoxifen and/or tranilast.
The cell viability and cytotoxicity was assessed using MTT and LDH assays; the apoptotic effects were examined by
TUNEL assay, acridine orange/ethidium bromide staining and DNA laddering, also the expression levels of bax and
bcl-2 genes were detected by real-time RT-PCR. The mRNA expression of TGF-β ligands and receptors examined
using real-time RT-PCR and TGF-β1 protein secretion levels were also evaluated by ELISA assay. Inhibitory effect of
these drugs on invasion and metastasis were tested by wound healing and matrigel invasion assay.
We found that combination of these drugs led to a marked increase in growth and proliferation inhibition
compared to either agent alone. Furthermore, bax and bcl-2 affected by tamoxifen and/or tranilast and resulted in
a significant increase in bax and decrease in bcl-2 mRNA expression. In addition, treatment with tamoxifen and/or
tranilast resulted in significant decreased in TGF-β1, 2, 3, TGF-βRI and II mRNA and TGF-β1 protein levels while
TGF-βRIII mRNA level was increased and invasion was also inhibited.
Conclusions: These findings indicate that tranilast, by synergistic effect, enhances the activity of tamoxifen and the
TGF-β pathway is a target for this combination therapy, therefore; we propose that this combined treatment may
be suitable selection in prevention of breast cancer.
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Apoptosis or programmed cell death provides an effective
non-inflammatory way to remove redundant or damaged
cells from tissues thereby acquiring tissue homeostasis [1].
Defective apoptosis and, in part, inappropriate prolifera-
tion, underpin the process of tumorigenesis [2] in addition,
resistance to apoptosis is an important feature for cancer
cells to invasion [3].
As estrogen significantly associated with the initi-
ation, progression, even recurrence of breast cancer [4],
anti-estrogens have important therapeutic potential in
endocrine therapy for breast cancer. Tamoxifen ((Z)-1-{4-* Correspondence: aghanbari@kums.ac.ir
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the Creative Commons Attribution License (ht
distribution, and reproduction in any medium[2-(dimethylamino) ethoxy] phenyl}-1, 2-diphenyl-1-bu-
tene) (TAM) is a synthetic non-steroidal anti-estrogenic
drug that widely used for the treatment or prevention of
breast carcinoma [5]. Despite the relative safety and sig-
nificant anti-neoplastic activities of tamoxifen, most ini-
tially responsive breast tumors develop resistance to its
[6]. Even though an improved understanding, resistance
to anti-estrogen therapy remains a significant clinical
problem. However, combination therapies of tamoxifen
with other drugs that aimed at the signaling pathways
underlying the development of resistance may be a po-
tential means of delaying the arrival of resistance.
One cytokine that may contribute to the metastatic
potential and possibly tamoxifen resistance of tumor cells
is transforming growth factor beta (TGF-β). There is three
isoforms of TGF-β: TGF-β1,-β2 and -β3 [7]. Cell functionsMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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discrete cell surface receptors, TGF-βRI, II and III [8].
TGF-β family regulates a diverse range of epithelial cell
processes including proliferation, apoptosis, differentiation,
adhesion and migration in a cell- and context-specific
manner [9]. The multiplicity of TGF-β actions in nearly all
cell types suggests that these have a complex and pivotal
role in several physiological and pathological processes.
TGF-β have an important role in normal mammary as a
potent inhibitor of epithelial proliferation and regulator of
mammary growth and development [10]. In addition,
TGF-β plays complex roles in breast carcinogenesis. Early
in mammary carcinogenesis the TGF-β signaling pathway
functions as a tumor suppressor [11] however, at later
stages, levels of TGF-β increase with tumor progression
suggesting that TGF-β is now stimulating breast cancer
progression [12].
The drug tranilast (N-[3′, 4′-dimethoxycinnamoyl]-
anthranilic acid), an anti-allergic agent, has been applied
for bronchial asthma, allergic rhinitis and atopic dermatitis,
also suppresses collagen synthesis in keloid or hypertrophic
scars [13,14]. The inhibitory effect of tranilast in different
cell types is probably by antagonizing and inhibiting
synthesis and secretion of TGF-β [15-19]. Since tranilast
responsibilities through TGF-β pathway, it seems also
tamoxifen influences this pathway [20], we hypothesize
that combination of tamoxifen and tranilast may an appro-
priate therapeutic option for breast cancer management.
In this paper, possible synergistic effect of tamoxifen with
tranilast was examined in the hope of creating a more ef-
fective anti-tumor treatment strategy.
Methods
Cell lines & drugs
MCF-7 (noninvasive human breast adenocarsinoma, ER-
and PR-positive) and MDA-MB-231 (metastatic human
breast adenocarsinoma, ER-, PR- and HER2-negative) ob-
tained from the National Cell bank of Iran (NCBI), were
grown in RPMI-1640 media supplemented with 10% (v/v)
fetal calf serum (FCS) and penicillin/streptomycin antibi-
otics. Cultures were maintained at 37°C in a humidified
atmosphere of 5% CO2 in air. TAM and tranilast were
purchased from Enzo Life Sciences and dissolved in di-
methyl sulfoxide (DMSO) so that the final dimethyl sulf-
oxide concentration in experimental wells did not exceed
0.5% (v/v). Aliquots of a 1000 μM stock solution of TAM
and tranilast were stored in dark at −70°C, defrosted and
diluted with cell culture medium to the desired concentra-
tion before use.
The concentrations used alone treatment were the fol-
lowing: TAM: 1, 2, 5, 10 and 20 μM; tranilast: 10, 20, 50,
100 and 200 μM. The treatment combinations used were:
2 μM of TAM with different concentrations of tranilast:
10, 20, 50, 100, and 200 μM for 48 h.Cell viability measurement
Cytotoxic effect of TAM and tranilast was determined
by MTT test. MCF-7 or MDA-MB-231 cells were seeded
in 96-well culture plates at 104 cells/well density. Cells
were allowed to attach for 24 h before drugs were added
to the medium. All drug concentrations were tested in
triplicate wells and the assays were performed in three
separate experiments. Following 48 h exposure at 37°C
and 5% CO2, 20 μl MTT solution (Cell Growth Assay;
Merck) (5 mg/ml in PBS) was added to each well and in-
cubated for 4 h at 37°C. The medium with MTT were
removed, and 100 μl DMSO was added to dissolve
formazan crystals at room temperature for 30 min. The
optical density (OD) of each well was measured using an
ELISA reader at 570 nm. The percentage of cell viability
was calculated according to the following equation:
Cell viability %ð Þ ¼ A570 sampleð Þ=A570 controlð Þ½ 
 100%
Lactate dehydrogenase (LDH) assay
MCF-7 or MDA-MB-231 cells were cultured in 96-well
plates (1×104 cells/well). The plates were incubated over-
night at 37°C and on the next day, 300 μl of culture
media containing drug doses were added to each well,
and the plates were incubated at 37°C in 5% CO2. 48 h
later, 100 μl of medium from each well was carefully
transferred to new plates. 100 μl of LDH substrate pre-
pared according to the manufacturer’s procedure (Cyto-
toxicity Detection Kit, Roche Chemical Co.) was added
to each well. After 20 min shaking at room temperature
lactate dehydrogenase activity was determined by change
in absorbance at 490 nm. All drug concentrations were
tested at least in triplicate wells and the assays were re-
peated independently three times.
TUNEL assay
TUNEL was carried out using an In Situ Cell Death De-
tection Kit, AP (Roche Diagnostics; Germany) according
to the manufacturer’s instructions. Briefly, after 48 h
treatment by 2 μM TAM, 200 μM tranilast or a combin-
ation two, the cells were fixed by adding 4% paraformalde-
hyde for 30 min. The fixed cells were washed in PBS,
permeabilized with 0.1% Triton X-100 for 5 min on ice,
and then incubated with 50 μl of terminal deoxynucleotidyl
transferase end-labeling solution for 60 min at 37°C in a
humidified chamber in the dark. Then, cells were coun-
terstained in PI staining solution for 4 min at room tem-
perature in the dark. The percentage of positively stained
cells per total number of cells was counted under a fluores-
cence microscope at a magnification of 40× in five random
fields and averaged.
Table 1 Oligonucleotide primers used in real-time RT-PCR
to amplify specific mRNAs together with sizes of
amplified products
Target mRNA Sequence (5′ to 3′) Product
size (bp)
GAPDH Forward actctggtaagtggatattgttgc 162
Reverse ggaagatggtgatgggatttc
BAX Forward tgtttgctgatggcaacttc 104
Reverse gatcagctcgggcactttag
BCL-2 Forward gggatgcctttgtggaacta 138
Darakhshan and Ghanbari Journal of Biomedical Science 2013, 20:76 Page 3 of 13
http://www.jbiomedsci.com/content/20/1/76Acridine orange/ethidium bromide (AO/EB) staining
MCF-7 or MDA-MB-231 were plated in 24-well plates
(105 cells/well) and incubated overnight in a humidified
5% CO2 incubator at 37°C for 24 h. At that time, cells
treated with 2 μM TAM, 200 μM tranilast or a combin-
ation two and incubated for 48 h. After that, cells har-
vested and stained with AO/EB dye mix (1 part of 100 μg/
ml of AO and 1 part of 100 μg/ml of EB in PBS) on a clean
microscope slide. The live, apoptotic and necrotic cells
were observed under the fluorescent microscope at a mag-
nification of 40×. Experiments were repeated for twice.Reverse ctcacttgtggcccaggtat
TGF-β1 Forward tgaaccggcctttcctgcttctcatg 152
Reverse gcggaagtcaatgtacagctgccgc
TGF-β2 Forward atgcggcctattgctttaga 185
Reverse taagctcaggaccctgctgt
TGF-β3 Forward cagggagaaaatccaggtca 179
Reverse cctggaaggcgtctaaccaag
TGF-βR1 Forward atcacctggccttggtcctgtgg 140
Reverse ggtcctcttcatttggcactcgatg
TGF-βR2 Forward gtctactccatggctctggt 197
Reverse atctggatgccctggtggtt
TGF-βR3 Forward tacagagagaggtcacact 112
Reverse gtcttcagatgccacaccagDNA gel electrophoresis (DNA laddering)
The MCF-7 and MDA-MB-231 cells were grown in ab-
sence or presence of 2 μM TAM, 200 μM tranilast and
combination of both for 48 h. Cellular DNA was then
extracted from each cell line. The cells were lysed with 1%
SDS in TE buffer and digested with proteinase K for 4 h at
56°C. The samples were extracted with phenol and chloro-
form and the DNA was precipitated with a 1/10 volume
of 3 M sodium acetate and an equal volume of ethanol,
pelleted at 13,000 × g and resuspended in TE buffer and
10 mg/ml of DNase-free RNase for 30 min at 37°C. Fi-
nally, extracted genomic DNAs was loaded and fractioned
on 2% agarose gels; gels were stained with ethidium brom-
ide and photographed. When DNA extracted from apop-
totic cells is subjected to gel electrophoresis, a typical
internucleosomal “ladder” of DNA fragments is produced.Real-time quantitative PCR (RQ-PCR) analysis
Total cellular RNAs were extracted from control or
drug-treated cell pellets, 48 h after treatment with 2 μM
TAM, 200 μM tranilast and combination both, using
RNeasy Mini kit (Qiagen) in accordance with the manu-
facturer”s protocol. First strand cDNA was synthesized
using QuantiTect Reverse Transcription Kit (Qiagen).
Numbers of cDNA copies were calculated from the ab-
sorbance at 260 nm. Aliquots of the cDNA were com-
bined with the QuantiFast® SYBER® Green PCR Master
Mix from Qiagen and primers, and assayed in triplicate
using a Rotor-Gene 6000 real-time RT-PCR. The primers
were designed using the program BioEdit and BLAST
searches (http://www.ncbi.nlm.nih.gov) carried out to con-
firm specificity of the selected nucleotide sequences and
properties of primers are summarized in Table 1.
Analysis and fold differences were determined using the
comparative 2 -ΔΔCT method. Quantitative values were
obtained from the threshold cycle (CT) number at which
the increase in fluorescent signal was associated with an
exponential increase of PCR product. The CT values from
samples were plotted on the standard curve and the copy
numbers was calculated with GAPDH as the internal
control.Measurement of secretion of TGF-β1 by ELISA assay
The amount of TGF-β1 released into the culture media
supernatant of breast cancer cells was quantitated using
the Quantikine human TGF-β1 (R&D Systems; Minne-
apolis, MN; USA) according to manufacturer’s guide-
lines. After 1 × 105 MCF-7 and MDA-MB-231 cells were
plated onto 48-well plates, cells were treated with 2 μM
TAM, 200 μM tranilast and a combination two for 48 h.
Supernatant from conditioned medium from TAM and/
or tranilast-treated cells were analyzed for TGF-β1 pro-
tein secretion by absorbance reading at 450 nm. Values
are expressed as secreted TGF-β1 pg/ml/1 × 105 cells.Wound-healing assay
The post-confluent MCF-7 and MDA-MB-231 cells were
used in this experiment. Wounds with a constant diameter
were made with a plastic tip (1 mm) and wounded mono-
layers were washed several times with medium to remove
cell debris. For each well five areas along the length of the
wound were chosen accidentally for photography under
phase contrast microscope on an inverted microscope.
After photography, the cells were incubated at 37°C in
a humidified incubator containing 5% CO2 in medium
containing 2% serum in the absence or 2 μM TAM,
200 μM tranilast and combination of both for 48 h and
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on day 0 were again taken at 48 h. Experiments were car-
ried out in triplicate.
In vitro cell invasion assay
Cell invasion was determined using transwell chambers
made from polycarbonate membrane filters with a pore
size of 8 μm. Transwell filters in 6-well plates were coated
with matrigel, hydrated for about 2 h in the tissue culture
incubator with 500 μl serum free culture media in the bot-
tom and 500 μl in the top of the chamber. After hydration
of the matrigel, 5 × 105 cells were plated in 500 μl serum-
free medium on top of chamber, while 2 ml medium 10%
FCS were placed in the lower chambers. TAM at 2 μM,
tranilast at 200 μM or a combination two were added to
the upper chambers. Cells without any drug were used as
vehicle. After 48 h of incubation, the filters were removed,
washed twice in PBS and fixed in 10% formalin for
15 min. After fixing at room temperature, the chambers
are rinsed in PBS and stained with 0.2% crystal violet
staining solution for 30 min. After washing the chambers
by PBS, the cells at the top of the matrigel membrane
were carefully removed by a number of cotton swabs. At
this time all cells that remain are the ones that have in-
vaded to the bottom side of the membrane. The number
of cells was counted in 10 fields at random chosen using
an inverted microscope at the 10× objective and plotted as
the percentage of invading cells.
Statistical analysis
Data were expressed as the mean ± standard error (SEM).
Statistical analysis was conducted by using one-way ana-
lysis of the variance (ANOVA) and t-test. All statistical
analyses were done using SPSS software 19.0 (SPSS, Inc.,
Chicago, IL, USA) and means were considered as statisti-
cally different for P < 0.05.
Results
Cytotoxic and anti-proliferative effects of TAM and/or
tranilast on breast cancer cells
The effects of TAM and tranilast alone or in combination
on percent cell survival and proliferation was evaluated by
MTT and LDH leakage assays. The results show that
TAM and/or tranilast exhibits the anti-proliferative effect
in a dose-dependent manner in both MCF-7 and MDA-
MB-231 cell lines (Figures 1 and 2). The percentage of
apoptotic cells in both cell lines after TAM and tranilast
either alone or combined treatment was dramatically
higher than in the untreated control cells. Especially, the
percentage of apoptotic cells in the combined treatment
was even higher than that in the treatment using the either
agent alone (p < 0.001 for each comparison). The addition
of tranilast to TAM caused a synergistic antiproliferative
effect on dysplastic cells and an additive growth inhibitioneffect in both cell lines (Figures 1 and 2). Comparing the
TAM and/or tranilast effect on growth between the two
cell lines yields a significantly greater effect in the MCF-7
cell line than in MDA-MB-231 cell line (Figures 1 and 2).
Apoptotic effects of TAM and/or tranilast on breast
cancer cells
We investigated whether the combination of TAM and
tranilast synergistically affected apoptosis of MCF-7 and
MDA-MB-231 cells. To determine the effect of TAM,
tranilast or combined both on apoptosis of MCF-7 and
MDA-MB-231 cells, cells was treated with 2 μM TAM,
200 μM tranilast alone or combination two for 48 h.
For analyzing apoptosis, several assays were employed,
including TUNEL assay, DNA fragmentation, AO/EB stain-
ing and to confirm apoptosis, we performed expression of
bcl-2 and bax using real-time RT-PCR.
TUNEL
The TUNEL reaction (TdT-mediated deoxy-uracil nick end
labeling) is used for analyzing DNA fragmentation by label-
ing the 3′-OH ends of the DNA strand breaks. This
method is based on the ability of terminal deoxynucleotidyl
transferase (TdT) to attach a fluorescein-conjugated deoxy-
uracil to the 3′-OH end of cut DNA [21]. Presented in
Figure 2 TUNEL staining clearly displayed apoptotic
cells in MCF-7 and MDA-MB-231 cells treated with
TAM and tranilast alone or a combination two compared
to untreated control cells. The numbers of apoptotic cells
were quantitated and presented as percentages (Figure 3f).
After treatment for 48 h, MCF-7 cells treated with TAM
and tranilast alone as many as 29% and 33% of cells
displayed TUNEL-positive staining, respectively, whereas
60% of the combination-treated cells were TUNEL-
positive. As shown in Figure 3B, TAM and tranilast also
induce a significant apoptosis in MDA-MB-231 cells (20%
and 30%, respectively) after 48 h exposure. Under the same
conditions, the percentage of TUNEL-positive MDA-MB-
231 cells significantly increased with the combination of
TAM and tranilast by 53%. As expected, the results show
that in both MCF-7 and MDA-MB-231 cell lines, com-
bination treatment resulted in higher levels of apoptosis
than either of them alone (p < 0.01). In addition, TUNEL
staining revealed an increased number of apoptotic cells
in MCF-7 cells (Figure 3A) compared with MDA-MB-
231 cells (Figure 3B).
Acridine orange/ethidium bromide (AO/EB) staining
Cell death was divided into two types, necrosis and apop-
tosis. Necrosis causes inflammation while apoptosis does
not. Induction of apoptosis in tumor cells has already been
used as an important indicator to detect the ability of che-
motherapeutic drugs to inhibit tumor growth [22].
Figure 1 The effects of TAM and/or tranilast on viability in MCF-7 (A) and MDA-MB-231 (B) cells. Cells were treated with TAM, tranilast
and combination both for 48 h. Control wells were treated with equivalent amount of media alone. Treatment with TAM and tranilast combined
significantly decreased the viability compared with TAM or tranilast alone. The results showed the mean and SE from triplicated experiments.
(*p < 0.05; **p < 0.01 ***p< 0.001 compared with control).
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AO and EB is considered the correct method for evaluating
the changed nuclear morphology [23]. AO permeates all
cells and the nuclei become green whereas EB is only taken
up by cells that their cytoplasmic membrane integrity is lost,
and their nuclei are stained red. EB also dominates over AO.
Thus, live cells will show a normal green nucleus. Early
apoptotic cells should give bright green nucleus with con-
densed or fragmented chromatin. Late apoptotic cells display
condensed and fragmented orange chromatin and necrotic
cells have a structurally normal orange nucleus [24].
The type of cell death induced by TAM, tranilast and
combination of both studied by fluorescent staining for
assessment of morphological changes. The Figure 4 ex-
hibited morphological changes of apoptosis including
cell shrinkage and chromatin condensation as compared
to control cells. The live, apoptotic and necrotic andFigure 2 TAM combined with tranilast additively inhibits survival of M
values of three experiments ± SE. p values were determined using one-wacells were monitored under the fluorescent microscope.
From the results of Figure 4 we found that in MCF-7
cells, live cells were seen in the control group, both early
and late apoptotic cells are seen in the presence of 2 μM
TAM, while late apoptotic cells are obvious in the pres-
ence of 200 μM of tranilast and in the presence of com-
bined treatment, the nearly all cells are late apoptotic
cells (Figure 4A).
In MDA-MB-231 cells, live cells with normal morph-
ology were seen in the control group, whereas early
apoptotic cells occurred in the group with 2 μM TAM,
early and late apoptotic cells were seen when 200 μM of
tranilast and in the presence of combination both a
number of cells in late stage, few cells also in early stage
(Figure 4B). These morphological changes suggest that
combination treatment significantly increased apoptosis
in both MCF-7 and MDA-MB-231 cells.CF-7 (A) and MDA-MB-231 (B) cells at 48 h. Shown are the mean
y ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001 compared with control).
Figure 3 Apoptotic potential of TAM and/or tranilast monitored by TUNEL staining in MCF-7 (A) and MDA-MB-231 (B) cells. Phase
micrographs of a negative control group; b positive control group; c 2 μM TAM; d 200 μM tranilast; e 2 μM TAM + 200 μM tranilast. f Columns
mean percentage of apoptotic cells from three independent experiments performed in triplicate. White arrows indicate yellow-stained nuclei
(TUNEL-positive cells). p values were determined using one-way-ANOVA (*p < 0.05 compared with control; **p < 0.01 compared with control).
Scale bar: 10 μm.
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This procedure is based on internucleosomal DNA cleav-
age, a characteristic biochemical hallmark of the apoptotic
mode of cell death.
Apoptosis of MCF-7 and MDA-MB-231 cells also de-
tected by analysis of DNA fragmentation on agarose gel,
a classical method of detecting the DNA ladders that ac-
company late apoptosis, in vitro. After treatment with 2 μMFigure 4 MCF-7 (A) and MDA-MB-231 (B) cells were stained by AO/EB
b in the presence of 2 μM TAM; c in the presence of 200 μM tranilast
normal morphology; green early apoptotic cells show nuclear margination
fragmented chromatin and apoptotic bodies. Scale bar: 10 μm. L = live celTAM, 200 μM tranilast and combination both for 48 h, the
DNA extracted from cells was electrophoresed on 2% agar-
ose gels. As shown in Figure 5, fragmented DNA was barely
detectable. However, substantial amounts of low-molecular-
weight DNA were present; indicating that either a small
subset of cells had undergone internucleosomal DNA di-
gestion or that only a fraction of each cell’s DNA had be-
come fragmented. Although DNA fragmentation has beenand observed under fluorescence microscope: a control group;
; d in the presence of in combination both. Green live cells show
and chromatin condensation. Late orange apoptotic cells showed
ls, A = early apoptotic cells, LA = late apoptotic cells, N = necrotic cells.
Figure 5 DNA fragmentation in MCF-7 and MDA-MB-231 cells
after treatment with 2 μM TAM, 200 μM tranilast and
combination both. Nuclear DNA was isolated from negative
control and treated cells after 48 h and analyzed by agarose gel
electrophoresis. M: DNA size marker; lane 1: 2 μM TAM; lane 2: 200
μM tranilast; lane 3: combination 2 μM TAM and 200 μM tranilast;
NC: negative control (DNA from untreated cells).
Figure 6 Expression levels of apoptotic factors on MCF-7 cells after T
(B) Bcl-2 (anti-apoptotic). Bax/bcl-2 values > 1 mean the cell line enters apo
**p < 0.01 compared with control).
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chemical hallmark of apoptosis, it may be delayed, partial
or absent in some cell types or experimental conditions.
Therefore, it seems that treatment of MCF-7 and MDA-
MB-231 cells with these doses not leads to significant DNA
fragmentation (Figure 5).
Previous studies show also that treatment of epithelial
cancer cell lines with a specific DNA-damaging agent
will produce high molecular weight DNA fragmentation
in the absence of nucleosomal laddering [25,26]. In
Addition, some apoptosis studies fail to exhibit the DNA
fragmentation pattern in the mammary carcinoma cells
[21,27].
Levels of bax and bcl-2 mRNA expression
To further investigate the apoptotic action of these two
agents, we used quantitative real-time PCR to study the
influence of them on bcl-2 and bax mRNA expression.
In many human cancers, the anti-apoptotic bcl-2 pro-
teins are overexpressed, or the pro-apoptotic proteins
like bax, have reduced expression [28]. This results in re-
sistance to a wide variety of cell death stimuli including
chemotherapeutic drugs [29].
Results of real-time quantitative PCR appeared to show
down-regulation of bcl-2 and upregulation of bax expres-
sion at 48 hours treatment (Figure 6A, B). Expression of
bcl-2 and bax was targets for TAM and tranilast as a sin-
gle or combination and after 48 h exposure, a significant
reduction of bcl-2 and induction of bax mRNA expression
was observed. Bax to bcl-2 mRNA ratio was determined
for MCF-7 cells: 3.4 in TAM treatment, 3.0 in tranilast
treatment and 8.4 in combined group and for MDA-MB-
231 cells: 1.7 in TAM treatment, 2.2 in tranilast treatmentAM and/or tranilast 48 h treatment. (A) Bax (pro-apoptotic) and
ptosis. p values were determined using one-way-ANOVA (*p < 0.05;
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to the anti-apoptotic was altered in favor of apoptosis
(Figure 6). Thus, the results suggest that an up-regulation
of bax and the corresponding down-regulation of bcl-2
mRNAs observed in this study may be one of the critical
mechanisms through which TAM and/or tranilast induces
apoptosis in breast cancer cells.
Effects of TAM and/or tranilast treatment on mRNA level
of TGF-β ligands and receptors in breast cancer cells
Exposure of cell cultures to TAM and tranilast either
alone or in combination for 48 h decreased expression
of TGF-β1, -β2, -β3 and TβRI, βRII mRNA. TGF-β1
mRNA levels were high but 48 h after TAM, tranilast or
combined treatment they were diminished approxi-
mately a 30% (p < 0.05), 70% (p < 0.01) and 92% (p <
0.001) in MCF-7 cells and 15%, 40% and 60% (p < 0.01)
in MDA-MB-231 cells (Figure 7). At the same time,Figure 7 TAM and tranilast regulate TGF-β ligands and receptors mRN
RT-PCR analysis in MCF-7 cells showed that TAM and tranilast as a single o
and TβRI, II mRNA. However, MCF-7 cells are stimulated by TAM and/or tra
were normalized against the internal control GAPDH and are expressed as
obtained in single experiments performed in triplicates. Different to contromRNA expression of TGF-β2 in treatment with TAM or
tranilast was down-regulated by 25% or 55% (p < 0.05) in
MCF-7 and 15% or 45% (p < 0.05) in MDA-MB-231 re-
spectively, while mRNA expression levels were decreased
by approximately 10-fold in the presence of TAM plus
tranilast (p < 0.01) in MCF-7 and 2-fold in MDA-MB-
231 cells (p < 0.05) (Figure 7). Incubation of the cells for
48 h with TAM, tranilast or both down-regulate the
mRNA encoding TGF-β3 by 40%, 60% (p < 0.05) and
80% in MCF-7 cells; and 10%, 30% and 65% in MDA-
MB-231 cells respectively (Figure 7). Expression TβRI in
TAM, tranilast or a combination two groups was de-
creased by approximately 2.5 (p < 0.05), 5 (p < 0.05) and
25-fold (p < 0.01) by MCF-7 cells, and 15%, 50% (p <
0.05) and 65% (p < 0.05) by MDA-MB-231 cells, respect-
ively. Incubation of the cultured cell lines with TAM,
tranilast or two drug decreased mRNA level encoding
TβRII by 50% (p < 0.01), 55% (p < 0.05) and 87% (p <A expression in MCF-7 and MDA-MB-231 cells. Quantitative
r in combination effectively decreased the expression of TGF-β1, 2, 3
nilast to increase TβRIII expression slightly. The real-time RT-PCR results
a percentage of control cells. All gene expression values were
l *p < 0.05, **p < 0.01, ***p < 0.001.
Darakhshan and Ghanbari Journal of Biomedical Science 2013, 20:76 Page 9 of 13
http://www.jbiomedsci.com/content/20/1/760.001) in MCF-7 and 15%, 30% (p < 0.05) and 55% (p <
0.01) in MDA-MB-231 cells, respectively (Figure 7).
However, Forty eight hours after TAM, tranilast or com-
bined treatment the type III receptor mRNA levels were
increased by about 20%, 50%, and 75% (p < 0.05) in
MCF-7 and without difference, 20% and 55% (p < 0.05)
in MDA-MB-231 cells, respectively compared with ve-
hicle cells (Figure 7).
Effect of TAM and/or tranilast on TGF-β1 secretion in
MCF-7 and MDA-MB-231 breast cancer cells
To evaluate the effects of TAM and/or tranilast on
TGF-β1 production from MCF-7 and MDA-MB-231 cells,
we measured using ELISA kit secreted TGF-β1 protein
level in the culture medium on cells treated with drugs
alone or combination of both. We found that treating
MCF-7 or MDA-MB-231 cells with TAM and tranilast as
a single treatment for 48 h significantly decreased TGF-β1
secretion from breast cancer cell lines, compared to con-
trol (p=0.21 for TAM and p < 0.01 for tranilast in MCF-7;
p=0.26 for TAM and p < 0.05 for tranilast in MDA-MB-
231 cells). The minimum protein levels were observed as
an effect of combination treatment (p < 0.01 in MCF-7
and p < 0.001 in MDA-MB-231 cells). These inhibitory ef-
fects also were higher in MCF-7 cells (Figure 8A) than in
MDA-MB-231 cells (Figure 8B).
Effects of TAM and/or tranilast on cell migration
and invasion
To evaluate the effects of TAM and tranilast as a single
or combined treatment on cell migration, we performed
wound (scratch) and transwell invasion assays in MCF-7Figure 8 Tranilast and TAM regulate the extracellular TGF-β1 protein
MDA-MB-231 cells were cultured without drugs (control) or in the presence
represent at least two independent experiments ± SEM. (A) TGF-β1 protein
medium from MDA-MB-231 cells (*p < 0.05, **p < 0.01, ***p < 0.001).and MDA-MB-231 cells. After 48 h treatment, cells in
the control group efficiently spread into the wound area
to such an extent that the wound boundary was not ap-
parent, while only some cells in TAM or tranilast treated
group spread forward in MCF-7 and MDA-MB-231
cells. The cell migration in combination group was lower
than either drugs alone. (Figure 9A, B). In migration
assay using a transwell system, migration was also de-
creased significantly with TAM or tranilast treatment.
Combination TAM with tranilast decreased cell invasive
ability of MCF-7 and MDA-MB-231 cells by 75% (p <
0.001) and 60% (p < 0.001), respectively (Figure 10A, B)
compared with the control.
Discussion
This study indicates that the effects of TAM with com-
bination tranilast may be enhanced, which shows the
mixture of TAM with tranilast produced a significant
additive cytotoxic effect in both cell lines. Our data also
demonstrated that TAM and tranilast inhibited MCF-7
and MDA-MB-231 cells proliferation by inducing apop-
tosis and the enhanced apoptosis may account for the
synergistic inhibition of the combination treatment.
Disabling of apoptosis is a central event in tumorigenesis,
and most chemotherapeutic drugs require functioning
apoptotic pathways [2]. Estrogen results in a general up-
regulation of genes regulating cell proliferation and survival
and the down-regulation of genes with anti-proliferative or
pro-apoptotic activity and the final resulting in growth
stimulation and apoptosis suppression [30]. Therefore, an-
tiestrogens are able to decrease cancer cell proliferation
and induce cell death signaling pathways [31].secreted from cultured human breast cancer cells. MCF-7 and
of 2 μM TAM, 200 μM tranilast or a combination two for 48 h. Results
levels in medium from MCF-7 cells; (B) TGF-β1 protein levels in
Figure 9 Effect of TAM/or tranilast on invasion in MCF-7 (A) and MDA-MB-231 (B) cells. Phase micrographs of cells were taken at 0 and
48 h after monolayer wounding. a control group in 0 day; b control group after 48 h; c MCF-7 cells treated with 2 μM TAM; d MCF-7 cells treated
with 200 μM tranilast; e MCF-7 cells treated with combination of two. Results are the average of three independent experiments, in triplicates.
Scale bar: 10 μm.
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http://www.jbiomedsci.com/content/20/1/76Consequently, tamoxifen treatment induces cell-cycle ar-
rest leads to an accumulation of cancer cells in G0/G1
phase of the cell cycle [32] and induce apoptosis of breast
cancer cells [33]. Morphological changes occur in apop-
totic cells provide the most important means of diag-
nosing apoptosis, which the chromatin condenses and
collapses into patches, followed by nuclear fragmenta-
tion and produce apoptotic bodies [34]. The Bcl-2 fam-
ily of proteins, with pro- and anti-apoptotic members,
regulates apoptosis during mammary gland develop-
ment and mammary tumorigenesis [35]. It has been de-
termined that both anti-apoptotic bcl-2 and pro-
apoptotic bax contribute to mammary apoptosis [36] as
well the bcl-2 gene is overexpressed in breast cancer
cells [37].
In this work, synergistic effect of combination TAM
and tranilast on induction apoptosis in breast cancer
in vitro examined using some methods and changes in
apoptotic cells evaluated. TAM and/or tranilast induced
characteristic morphological modifications associated with
apoptosis, including condensation of chromatin and DNA
cleavage, as well expression of apoptosis regulators, bax
and bcl-2 assessed and confirmed. We have demonstrated
that the combination of TAM and tranilast resulted in a
synergistic effect on both growth inhibition and apoptosis
induction.
Studies have revealed that TAM is also effective in
treatment of ER-negative tumors including breast
[38]. The apoptosis induced by TAM is not reversible
by addition of estrogens, telling that ER-independent
induction of apoptosis could be a dominant mechan-
ism of action in ER-negative breast tumors [39]. On
the other side, inhibition of breast cancer growth by
tamoxifen appears to be mediated by TGF-β signaling
pathway [20]. Tamoxifen implements its effects both
directly through the promotion of apoptosis andinhibition of mitosis, and indirectly through the TGF-β. It
is found that changed expression of growth factors, among
them TGF-β, is crucial for carcinogenesis [40]. TGF-β
plays pivotal role in breast cancer. Some studies show that
TGF-β is a potent inhibitor of primary mammary epithe-
lial cells and breast cancer cell lines and reduced levels of
TGF-β signaling are observed in several cancers [41,42].
Conversely, a large number of reports indicate that TGF-β
turn into a promoter of progression in advanced tumor
stages [43,44] by stimulation of angiogenesis, extracellular
matrix degradation and metastasis [45]. Studies have
shown a causal association between TGF-β and motility,
invasiveness and metastasis [46] also survival and malig-
nancy of human breast carcinoma cells [47]. Expression of
TGF-β1, β-2, and β-3 mRNAs has been detected in hu-
man breast cancer cells [48]. Moreover, autocrine/para-
crine TGF-β and its downstream Smad signaling play a
survival role in breast cancer cells also Epithelial-
Mesenchymal Transition (EMT) and lead to acquired
tamoxifen resistance [49].
In this study tranilast with TAM down-regulated the
expression of TGF-β1, β-2, and β-3 also TβRI and TβRII
from breast cancer cells. TβRIII or betaglycan is a sup-
pressor of breast cancer progression and that, when
TβRIII expression is restored, invasion, angiogenesis, and
metastasis is inhibited in vivo [50]. In this study, tranilast
and TAM increased the expression of TβRIII slightly. Des-
pite these uncertainties, it has become apparent that TGF-
β gains a growth-promoting role and treatments that
block TGF-β signaling have shown some efficacy in clin-
ical trials [51].
Recently, there has been an increasing interest in evalu-
ating combining chemotherapeutic drugs with other sub-
stances [52-55] for achieving better treatment with less
toxicity in breast cancer. In this regard, we had chosen
tranilast as an adjuvant to TAM in breast cancer therapy.
Figure 10 Tranilast enhances anti-migratory activity of TAM in MCF-7 (A) and MDA-MB-231 (B) cells invasion in vitro. Tamoxifen, tranilast
and combination both inhibits MCF-7 cell invasion through matrigel. Phase micrograph of invading MCF-7 (A) and MDA-MB-231 (B) cells:
a control group; b cells treated with 2 μM TAM; c cells treated with 200 μM tranilast; d cells treated with combination of two; e Quantification of
cell invasion (*p < 0.05, **p < 0.01, ***p < 0.001). Scale bar: 10 μm.
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http://www.jbiomedsci.com/content/20/1/76Tranilast revealed no significant side effects even when
administered for time-consuming periods and several re-
ports showed that tranilast inhibits the proliferation of
several cancer cell types including breast [56-59]. The in-
hibitory mechanisms have been elucidated as regards
tranilast function, including its role in inhibiting and an-
tagonizing the TGF-β pathway [60].
In the present study we show, tranilast as a single
or in combination with TAM can regulate TGF-β
isoforms and receptors gene expression and TGF-β1
protein secretion from human breast cancer cells. In
addition, we demonstrate that tranilast and/or TAM
inhibit migration and invasion of MCF-7 and MDA-
MB-231 cells and these results could explain thebeneficial effects of this combination in management
of breast cancer. These results suggest that the addi-
tive effect between TAM and tranilast in inhibiting
breast cancer may in part reflect the ability of both
drugs to modulate and suppress TGF-β in breast can-
cer cells.
The anti-tumor effects observed here occurred at
concentrations of tranilast that may well be achieved
in vivo. If the results are confirmed in vivo, they may
be significant clinically. Future researches on the
detailed mechanisms of these using tranilast and tam-
oxifen will facilitate the understanding of the synergistic
effects of these drugs on apoptosis as well TGF-β
pathway.
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http://www.jbiomedsci.com/content/20/1/76Conclusions
These results suggest that tamoxifen plus tranilast could be
a promising combination therapy for future clinical trials in
breast cancer patients. However further studies are also
needed to investigate the expression of TGF-β pathway
components in breast cancer contributes to the regulation
of metastasis. Nonetheless, our study suggests that TGF-β
pathway may be targeted for the inhibition of invasion in
breast cancer cells. In a line, we believe that the present
data may lead to new therapeutic options for breast cancer.
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